Fresenius closer and closer to marketing biosimilars

Fresenius yesterday took the opportunity to demonstrate to investors and shareholders that purchasing Merck KGaA’s biosimilars portfolio has been a wise decision. Indeed, Fresenius Kabi yesterday submitted a Marketing Authorization Application to the European Medicines Agency (EMA) for its biosimilar to blockbuster Humira, for the treatment of inflammatory autoimmune disorders. The drug is expected to be marketed as of 2019. Fresenius’ shares yesterday rose over 2% (Frankfurt).

(Source: FAZ)